The crossover design for migraine preventives: an analyses of four randomized placebo-controlled trials

Table 1 Summary of study details which differ between studies

Authors	Schrader et al. [11]	Tronvik et al. [12]	Stovner et al. [13]	Hagen et al. [14]
Publication year	2001	2003	2014	2015
Number included	60¹	60²	72	72
Age range at inclusion	19–59	18–65	18–65	18–65
Number of migraine attacks per month at inclusion	2–6	2–6	≥2	≥2
Number of treatment periods	2	2	3	2
Duration of follow-up, weeks	30	32	48	32
Active substance(s)	Lisinopril	Candesartan	Candesartan and Propanolol³	Acetyl-L-carnitine
Effect of active versus placebo	Yes	Yes	Yes	No
Blinding	Double	Double	Triple⁴	Triple⁴
Placebo tablets in baseline period	Yes	Yes	No	No
Placebo tablets in washout period	Yes	Yes	No	No

¹63 entered baseline period, but 3 were not randomized after run-in period because of < 2 attacks/month (n = 2) or for no specific reason (n = 1)
²75 entered baseline period, but 15 were excluded because of < 2 attacks/month (n = 5), > 6 attack/month (n = 7) or for other reasons (n = 3)
³This study was a double crossover study
⁴Meaning that the statisticians were also blinded

ISSN: 1129-2377